Instrument Inactif

Autres langues Refocus Group, Inc. Other OTC

Actions

04/12/17	Refocus Group Submits Final Module for Pre-Market Approval of the VisAbility Micro Insert System for Presbyopia
04/05/17	Refocus Group Concludes 12-Month Follow-Up for Phase 3 Clinical Trial on the Visability(Tm) Micro-Insert System for Presbyopia
05/05/16	Refocus Group Inc. announced that it has received $15 million in funding from WP Global Partners, Inc., MedCare Investment Funds
16/10/13	Refocus Group Inc. Announces Executive Changes